Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trialHisashi Saji, Hisao Asamura, Ichiro Yoshino et al.|The Lancet|2022Cited by 1.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trialKenji Suzuki, Hisao Asamura, Hisashi Saji et al.|Journal of Thoracic and Cardiovascular Surgery|2019Cited by 496
Mitochondrial metabolism as a potential novel therapeutic target for lung adenocarcinomaMakoto Fujiwara, Morihito Okada|Research Square|2023Cited by 0